Merav Cohen

This study develops a bispecific antibody that enhances T-cell engagement with AXL+ cells, improving anti-PD-1 therapy efficacy in HNSCC by remodeling the tumor microenvironment.

This study identifies decoy antibodies targeting extracellular HSP70 on melanoma-derived melanosomes, which inhibit tumor growth and survival in preclinical models and correlate with clinical response to immunotherapy.

The paper identifies TREM2-expressing macrophages as predictors of response to PD-1 blockade in HCC patients using clinical and spatial transcriptomic data.

The paper shows that T cell-derived IFN-γ suppresses TFH differentiation and antibody responses by acting through dendritic cells, not directly on CD4+ T cells.